Can we prevent Parkinson’s disease with n-3 polyunsaturated fatty acids?

Bibliography

• Aminoff MJ: Parkinson’s disease and other extrapyramidal disorders. In: Harrison’s Principles of Internal Medicine. Kasper DL, Braunwald E, Fauci AS et al. (Eds). McGraw-Hill Professional, NY, USA 2399–2406 (2004)s
   Google Scholar
• Brice A: Genetics of Parkinson’s disease: LRRK2 on the rise. Brain 128(Pt 12), 2760–2762 (2005)
   Google Scholar
• Gasser T: Genetics of Parkinson’s disease. Curr. Opin. Neurol. 18(4), 363–369 (2005)
   Google Scholar
• Feany MB: New genetic insights into Parkinson’s disease. N. Engl. J. Med. 351(19), 1937–1940 (2004)
   Google Scholar
• Farrer MJ: Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7(4), 306–318 (2006)
   Google Scholar
• Tanner CM, Ottman R, Goldman SM et al.: Parkinson disease in twins: an etiologics
   Google Scholar
• Schapira AH: Disease modification in Parkinson’s disease. Lancet Neurol. 3(6), 362–368 (2004)
   Google Scholar
• Moore DJ, West AB, Dawson VL, Dawson TM: Molecular pathophysiology of Parkinson’s disease. Annu. Rev. Neurosci. 28, 57–87 (2005)
   Google Scholar
• Beal MF: Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325–334 (2001)
   Google Scholar
• Betarbet R, Sherer TB, Greenamyre JT: Animal models of Parkinson’s disease. Bioessays 24, 308–318 (2002)
   Google Scholar
• Dawson T, Mandir A, Lee M: Animal models of Parkinson’s disease: pieces of the same puzzle? Neuron 35, 219–222 (2002)
   Google Scholar
• Di Monte DA, Lavasani M, Manning-Bog AB: Environmental factors in Parkinson’s disease. Neurotoxicology 23, 487–502 (2002)
   Google Scholar
• Landrigan PJ, Sonawane B, Butler RN, Trasande L, Callan R, Droller D: Early environmental origins of neurodegenerative disease in later life. Environ. Health Perspect. 113(9), 1230–1233 (2005)
   Google Scholar
• Ascherio A, Chen H, Weisskopf MG et al.: Pesticide exposure and risk for Parkinson’s disease. Ann. Neurol. 60(2), 197–203 (2006)
   Google Scholar
• Dick FD: Parkinson’s disease and pesticide exposures. Br. Med. Bull. 79–80, 219–231 (2006)
   Google Scholar
• Dinis-Oliveira RJ, Remiao F, Carmo H et al.: Paraquat exposure as an etiological factor of Parkinson’s disease. Neurotoxicology 27(6), 1110–1122 (2006)
   Google Scholar
• Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK: Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson’s disease accelerate age-related neurodegeneration. J. Neurosci. 27(26), 6914–6922 (2007)
   Google Scholar
• Cicchetti F, Lapointe N, Roberge-Tremblay A et al.: Systemic exposure to paraquat and maneb models early Parkinson’s disease in young adult rats. Neurobiol. Dis. 20(2), 360–371 (2005)
   Google Scholar
• Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V: Environmental exposures in elderly Canadians with Parkinson’s disease. Can. J. Neurol. Sci. 22, 232–234 (1995)
   Google Scholar
• Corasaniti MT, Strongoli MC, Rotiroti D, Bagetta G, Nistico G: Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol. Toxicol. 83(1), 1–7 (1998)
   Google Scholar
• Chen H, O’Reilly E, McCullough ML et al.: Consumption of dairy products and risk of Parkinson’s disease. Am. J. Epidemiol. 165(9), 998–1006 (2007)
   Google Scholar
• de Lau LM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM: Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67(2), 315–318 (2006)
   Google Scholar
• Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J: Coffee and tea consumption and the risk of Parkinson’s disease. Mov. Disord. 22(15), 2242–2248 (2007)
   Google Scholar
• Datla KP, Zbarsky V, Rai D et al.: Shortterm supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson’s disease. J. Am. Coll. Nutr. 26(4), 341–349 (2007)
   Google Scholar
• Wassef R, Haenold R, Hansel A, Brot N, Heinemann SH, Hoshi T: Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson’s-like symptoms. J. Neurosci. 27(47), 12808–12816 (2007)
   Google Scholar
• Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36(9), 945–959 (2001)
   Google Scholar
• Julien C, Berthiaume L, Hadj-Tahar A et al.: Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem. Int. 48(5), 404–414 (2006)
   Google Scholar
• Calon F, Lim GP, Yang F et al.: Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron 43(5), 633–645 (2004)
   Google Scholar
• Calon F, Lim GP, Morihara T et al.: Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer’s disease. Eur. J. Neurosci. 22(3), 617–626 (2005)
   Google Scholar
• Lim GP, Calon F, Morihara T et al.: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25(12), 3032–3040 (2005)
   Google Scholar
• Oksman M, Iivonen H, Hogyes E et al.: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on -amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23(3), 563–572 (2006)
   Google Scholar
• Green KN, Martinez-Coria H, Khashwji H et al.: Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid- and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 27(16), 4385–4395 (2007)
   Google Scholar
• Hashimoto M, Hossain S, Shimada T et al.: Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats. J. Neurochem. 81(5), 1084–1191 (2002)
   Google Scholar
• Bazan NG: Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15(2), 159–166 (2005)
   Google Scholar
• Jump DB: The biochemistry of n-3 polyunsaturated fatty acids. J. Biol. Chem. 277(11), 8755–8878 (2002)
   Google Scholar
• Kim HY: Novel metabolism of docosahexaenoic acid in neural cells. J. Biol. Chem. 282(26), 18661–18665 (2007)
   Google Scholar
• Hunot S, Hirsch EC: Neuroinflammatory processes in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3), S49–S58; discussion S58–S60 (2003)
   Google Scholar
• Jenner P: Oxidative stress in Parkinson’s disease. Ann. Neurol. 53(Suppl. 3), S26–S36; discussion S36–S38 (2003)
   Google Scholar
• Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD: Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov. Disord. 14(1), 21–27 (1999)
   Google Scholar
• Logroscino G, Marder K, Graziano J et al.: Dietary iron, animal fats, and risk of Parkinson’s disease. Mov. Disord. 13(Suppl. 1), 13–16 (1998)
   Google Scholar
• Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R: Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case–control study. Ann. Neurol. 39(1), 89–94 (1996)
   Google Scholar
• Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL: Adult nutrient intake as a risk factor for Parkinson’s disease. Int. J. Epidemiol. 28(6), 1102–1109 (1999)
   Google Scholar
• Abbott RD, Ross GW, White LR et al.: Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu–Asia Aging Study. J. Neurol. 250(Suppl. 3), III30–III39 (2003)
   Google Scholar
• Hellenbrand W, Seidler A, Boeing H et al.: Diet and Parkinson’s disease. I: a possible role for the past intake of specific foods and food groups. Results from a selfadministered food-frequency questionnaire in a case–control study. Neurology 47(3), 636–643 (1996)
   Google Scholar
• Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR: Case–control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46(5), 1270–1274 (1996)
   Google Scholar
• de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM: Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64(12), 2040–2045 (2005)
   Google Scholar
• Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A: Dietary intakes of fat and risk of Parkinson’s disease. Am. J. Epidemiol. 157(11), 1007–1014 (2003)
   Google Scholar
• Gao X, Chen H, Fung TT et al.: Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86(5), 1486–1494 (2007)
   Google Scholar
• Bezard E: A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behav. Pharmacol. 17(5–6), 379–382 (2006)
   Google Scholar
• Hirsch EC: How to judge animal models of Parkinson’s disease in terms of neuroprotection. J. Neural Transm. Suppl. 70, 255–260 (2006)
   Google Scholar
• Dauer W, Przedborski S: Parkinson’s disease: mechanisms and models. Neuron 39(6), 889–909 (2003)
   Google Scholar
• Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C, Cicchetti F: Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol. Aging 27(6), 862–870 (2006)
   Google Scholar
• Jackson-Lewis V, Przedborski S: Protocol for the MPTP mouse model of Parkinson’s disease. Nat. Protoc. 2(1), 141–151 (2007)
   Google Scholar
• Bousquet M, Saint-Pierre M, Julien C, Salem NJ, Cicchetti F, Calon F: Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. FASEB J. doi: 10.1096/fj.07-9677com (2007) (Epub ahead of print)
   Google Scholar
• Rapoport SI, Rao JS, Igarashi M: Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot. Essent. Fatty Acids 77(5–6), 251–261 (2007)
   Google Scholar
• Lin YH, Salem NJ: Whole body distribution of deuterated linoleic and -linolenic acids and their metabolites in the rat. J. Lipid Res. 48(12), 2709–2724 (2007)
   Google Scholar
• Igarashi M, DeMar JCJ, Ma K, Chang L, Bell JM, Rapoport SI: Docosahexaenoic acid synthesis from -linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. J. Lipid Res. 48(5), 1150–1158 (2007)
   Google Scholar
• Salem N Jr: Omega-3 fatty acids: molecular and biochemical aspects. In: New Protective Roles for Selected Nutrients. Spiller GA, Scala J (Eds). Wiley-Liss, NY, USA 109–228 (1989)
   Google Scholar
• Rapoport SI: In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J. Pediatr. 143(4 Suppl.), S26–S34 (2003)
   Google Scholar
• Demar JC Jr, Ma K, Bell JM, Rapoport SI: Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J. Neurochem. 91(5), 1125–1137 (2004)
   Google Scholar
• Alessandri JM, Guesnet P, Vancassel S et al.: Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod. Nutr. Dev. 44(6), 509–538 (2004)
   Google Scholar
• Roberts LJ, Fessel JP, Davies SS: The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol. 15(2), 143–148 (2005)
   Google Scholar
• Nourooz-Zadeh J, Halliwell B, Anggard EE: Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 236(2), 467–472 (1997)
   Google Scholar
• Lynch AM, Loane DJ, Minogue AM et al.: Eicosapentaenoic acid confers neuroprotection in the amyloid- challenged aged hippocampus. Neurobiol. Aging 28(6), 845–855 (2007)
   Google Scholar
• Mukherjee PK, Chawla A, Loayza MS, Bazan NG: Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids 77(5–6), 233–238 (2007)
   Google Scholar
• Gronn M, Christensen E, Hagve TA, Christophersen BO: Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim. Biophys. Acta 1081(1), 85–91 (1991)
   Google Scholar
• Brossard N, Croset M, Pachiaudi C, Riou JP, Tayot JL, Lagarde M: Retroconversion and metabolism of [13C];22:6n-3 in humans and rats after intake of a single dose of [13C]22:6n-3- triacylglycerols. Am. J. Clin. Nutr. 64(4), 577–586 (1996)
   Google Scholar
• Stahl LA, Begg DP, Weisinger RS, Sinclair AJ: The role of omega-3 fatty acids in mood disorders. Curr. Opin Investig. Drugs 9(1), 57–64 (2008)
   Google Scholar
• Ravina BM, Fagan SC, Hart RG et al.: Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology 60(8), 1234–1240 (2003)
   Google Scholar
• Olanow CW, Jankovic J: Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesistargeted, disease-modifying strategy. Mov. Disord. 20(Suppl. 11), S3–S10 (2005)
   Google Scholar
• Calon F, Cole G: Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 77(5–6), 287–293 (2007)
   Google Scholar
• Calon F: Nonpatentable drugs and the cost of our ignorance. Canadian Med. Association J. 174(4), 483–484 (2006).
   Google Scholar